Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) CFO Jean M. Franchi sold 2,000 shares of the stock in a transaction on Monday, June 16th. The shares were sold at an average price of $52.26, for a total transaction of $104,520.00. Following the completion of the sale, the chief financial officer now owns 67,530 shares of the company's stock, valued at approximately $3,529,117.80. This represents a 2.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Disc Medicine Stock Performance
NASDAQ:IRON traded up $0.04 during mid-day trading on Wednesday, reaching $50.09. 319,600 shares of the company's stock were exchanged, compared to its average volume of 346,246. Disc Medicine, Inc. has a one year low of $30.82 and a one year high of $68.73. The firm has a market capitalization of $1.73 billion, a PE ratio of -12.78 and a beta of 0.73. The business's fifty day simple moving average is $46.44 and its two-hundred day simple moving average is $53.08. The company has a debt-to-equity ratio of 0.04, a quick ratio of 37.65 and a current ratio of 37.65.
Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($1.02) EPS for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.03). Analysts anticipate that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Disc Medicine
A number of hedge funds have recently bought and sold shares of IRON. Amalgamated Bank increased its holdings in Disc Medicine by 38.6% in the 1st quarter. Amalgamated Bank now owns 787 shares of the company's stock valued at $39,000 after buying an additional 219 shares during the period. Tower Research Capital LLC TRC increased its holdings in Disc Medicine by 47.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company's stock valued at $52,000 after buying an additional 266 shares during the period. Teacher Retirement System of Texas increased its holdings in Disc Medicine by 8.9% in the 4th quarter. Teacher Retirement System of Texas now owns 4,857 shares of the company's stock valued at $308,000 after buying an additional 396 shares during the period. Sterling Capital Management LLC increased its holdings in Disc Medicine by 798.4% in the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company's stock valued at $36,000 after buying an additional 503 shares during the period. Finally, Arizona State Retirement System increased its holdings in Disc Medicine by 12.5% in the 1st quarter. Arizona State Retirement System now owns 5,315 shares of the company's stock valued at $264,000 after buying an additional 590 shares during the period. 83.70% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of analysts have commented on IRON shares. TD Cowen assumed coverage on shares of Disc Medicine in a research note on Thursday, February 27th. They issued a "buy" rating for the company. Wedbush restated an "outperform" rating and set a $90.00 target price on shares of Disc Medicine in a research note on Monday. Cantor Fitzgerald raised their target price on shares of Disc Medicine from $99.00 to $132.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 18th. BMO Capital Markets raised their target price on shares of Disc Medicine from $112.00 to $120.00 and gave the stock an "outperform" rating in a research note on Monday, May 12th. Finally, Scotiabank raised their target price on shares of Disc Medicine from $73.00 to $75.00 and gave the stock a "sector outperform" rating in a research note on Monday, March 3rd. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Disc Medicine has an average rating of "Buy" and an average target price of $96.70.
Check Out Our Latest Stock Analysis on Disc Medicine
About Disc Medicine
(
Get Free Report)
Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Disc Medicine, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Disc Medicine wasn't on the list.
While Disc Medicine currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
